ARCH Venture Partners XII, LLC sold CTY

October 19, 2026 · Form 4 insider transaction

ARCH Venture Partners XII, LLC sold 1,845,585 shares of City Therapeutics, Inc. at $0.00 per share, a transaction worth N/A. The trade was recorded as conversion of a derivative and disclosed on an SEC Form 4, filed 0 days after the transaction.

Direction
Disposed (sell-side)
Shares
1,845,585
Price
$0.00
Total value
N/A
Role10% owner
SecuritySeries B convertible preferred stock
Transaction codeC: Conversion of a derivative
Transaction dateOctober 19, 2026
Filing dateOctober 19, 2026
Shares owned after0
OwnershipIndirect
10b5-1 planNo
AmendedNo

Footnotes

Each share of Series Seed convertible preferred stock, Series A convertible preferred stock and Series B convertible preferred stock (collectively, the "Preferred Stock") was convertible into Common Stock of the Issuer on a one-to-1.0983 basis at the option of the holder, and automatically converted into Common Stock upon the closing of the Issuer's initial public offering on October 19, 2026 without payment of consideration. The Preferred Stock had no expiration date.; Shares held directly by ARCH Venture Fund XII, L.P. ("ARCH XII"). ARCH Venture Partners XII, L.P. ("AVP XII LP") is the sole general partner of ARCH XII. ARCH Venture Partners XII, LLC ("AVP XII LLC") is the sole general partner of AVP XII LP. Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen are members of the investment committee of AVP XII LLC (the "AVP XII LLC Committee Members"). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XII LLC and the AVP XII LLC Committee Members disclaims beneficial ownership except to the extent of their pecuniary interest therein, if any. Mr. Nelsen serves on the board of directors of the Issuer and is filing his own Form 4 separately.

View the original Form 4 on SEC EDGAR